{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T22:23:43Z","timestamp":1785018223638,"version":"3.55.0"},"reference-count":42,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,9]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Hemophagocytic lymphohistiocytosis (HLH) is a hyperinflammatory syndrome that complicates hematologic malignancies. The Optimized HLH Inflammatory (OHI) index, based solely on the combined elevation of soluble CD25 (sCD25; &amp;gt;3900 U\/mL) and ferritin (1000 ng\/mL) levels, predicts mortality more effectively than the conventional HLH criteria. This study aimed to determine whether mortality in OHI-positive (OHI+) patients is primarily caused by lymphoma or inflammation-related causes. In a multicenter, retrospective study of patients with newly diagnosed lymphoma with sCD25 and ferritin measurements available, patients were classified as OHI+ or OHI negative (OHI\u2212). The 1-year and 3-year overall survival (OS), event-free survival, and causes of death were analyzed, along with predicted vs observed mortality based on other lymphoma-relevant prognostic indexes. Among 135 patients with lymphoma (70 OHI\u2212 and 65 OHI+), OHI+ patients had significantly lower OS at 1 year (33% vs 81%; P &amp;lt; .0001) with a median survival of 190 days. OHI+ patients had a 13-fold increased mortality risk (odds ratio, 13.3; 95% confidence interval, 6.0-28.5) despite similar predicted OS based on conventional indexes (72% vs 65%; P = .46). Mortality causes differed significantly. A total of 58% of OHI+ patients died from multiorgan failure, whereas only 6% died from progressive lymphoma. In contrast, 43% of the OHI\u2212 patients died from lymphoma progression. The incorporation of etoposide into lymphoma-directed treatment was associated with improved OS in OHI+ T\u2013cell lymphomas (P = .007). These findings underscore the clinical significance of the OHI index as a prognostic tool in lymphoma, to elucidate the mechanisms of mortality, and to identify a high-risk subgroup for which tailored treatments may lead to improved outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014005","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T16:11:16Z","timestamp":1744992676000},"page":"4515-4525","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":11,"title":["The OHI index predicts early mortality from organ dysfunction and survival benefit from etoposide in patients with lymphoma"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9837-4427","authenticated-orcid":false,"given":"Adi","family":"Zoref-Lorenz","sequence":"first","affiliation":[{"name":"1Hematology Institute, Meir Medical Center, Kfar Saba, Israel"},{"name":"2Division of Immunobiology, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH"},{"name":"3Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2017-963X","authenticated-orcid":false,"given":"Jun","family":"Murakami","sequence":"additional","affiliation":[{"name":"4Clinical Laboratory, Transfusion Medicine and Cell Therapy, University of Toyama, Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronit","family":"Gurion","sequence":"additional","affiliation":[{"name":"3Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel"},{"name":"5Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1646-813X","authenticated-orcid":false,"given":"Swaminathan P.","family":"Iyer","sequence":"additional","affiliation":[{"name":"6Department of Lymphoma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uri","family":"Abadi","sequence":"additional","affiliation":[{"name":"1Hematology Institute, Meir Medical Center, Kfar Saba, Israel"},{"name":"3Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3980-3305","authenticated-orcid":false,"given":"Inbar","family":"Cohen","sequence":"additional","affiliation":[{"name":"3Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel"},{"name":"5Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6148-5177","authenticated-orcid":false,"given":"Gaurav","family":"Goyal","sequence":"additional","affiliation":[{"name":"7Division of Hematology-Oncology, University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3157-3720","authenticated-orcid":false,"given":"Shehab","family":"Mohamed","sequence":"additional","affiliation":[{"name":"8Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"},{"name":"9Department of Oncology, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2711-5575","authenticated-orcid":false,"given":"Sarah","family":"Nikiforow","sequence":"additional","affiliation":[{"name":"10Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abd El Haleem","family":"Natour","sequence":"additional","affiliation":[{"name":"3Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel"},{"name":"11Department Internal Medicine \u201cA,\u201d Meir Medical Center, Kfar Saba, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiri","family":"Weinstein","sequence":"additional","affiliation":[{"name":"3Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel"},{"name":"12Division of Clinical Immunology, Angioedema and Allergy Institute, Sheba Medical Center, Tel Hashomer, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3763-5694","authenticated-orcid":false,"given":"Joanne","family":"Yacobovich","sequence":"additional","affiliation":[{"name":"3Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel"},{"name":"13Division of Hematology-Oncology, Schneider Children\u2019s Medical Center of Israel, Petah Tikva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6268-3300","authenticated-orcid":false,"given":"Hae Lin","family":"Cho","sequence":"additional","affiliation":[{"name":"14Division of Hematology, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9973-639X","authenticated-orcid":false,"given":"Pia","family":"Raanani","sequence":"additional","affiliation":[{"name":"3Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel"},{"name":"5Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[{"name":"3Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel"},{"name":"15Division of Hematology, Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Berliner","sequence":"additional","affiliation":[{"name":"14Division of Hematology, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-373X","authenticated-orcid":false,"given":"Naval","family":"Daver","sequence":"additional","affiliation":[{"name":"8Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9064-8139","authenticated-orcid":false,"given":"Gilad","family":"Itchaki","sequence":"additional","affiliation":[{"name":"1Hematology Institute, Meir Medical Center, Kfar Saba, Israel"},{"name":"3Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6938-2540","authenticated-orcid":false,"given":"Shai","family":"Izraeli","sequence":"additional","affiliation":[{"name":"3Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel"},{"name":"13Division of Hematology-Oncology, Schneider Children\u2019s Medical Center of Israel, Petah Tikva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6804-1472","authenticated-orcid":false,"given":"Martin","family":"Ellis","sequence":"additional","affiliation":[{"name":"1Hematology Institute, Meir Medical Center, Kfar Saba, Israel"},{"name":"3Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Jordan","sequence":"additional","affiliation":[{"name":"2Division of Immunobiology, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH"},{"name":"16Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children\u2019s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"issue":"3","key":"2025090911213696700_bib1","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2352-3026(21)00366-5","article-title":"Malignancy-associated haemophagocytic lymphohistiocytosis","volume":"9","author":"Setiadi","year":"2022","journal-title":"Lancet Haematol"},{"issue":"23","key":"2025090911213696700_bib2","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood.2018894618","article-title":"Recommendations for the management of hemophagocytic lymphohistiocytosis in adults","volume":"133","author":"La Ros\u00e9e","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2025090911213696700_bib3","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1532\/IJH97.07012","article-title":"Nationwide survey of hemophagocytic lymphohistiocytosis in Japan","volume":"86","author":"Ishii","year":"2007","journal-title":"Int J Hematol"},{"issue":"35","key":"2025090911213696700_bib4","doi-asserted-by":"crossref","first-page":"59977","DOI":"10.18632\/oncotarget.19230","article-title":"A systematic review of malignancy-associated hemophagocytic lymphohistiocytosis that needs more attentions","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"issue":"17","key":"2025090911213696700_bib5","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1002\/cncr.30826","article-title":"A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults","volume":"123","author":"Daver","year":"2017","journal-title":"Cancer"},{"issue":"8","key":"2025090911213696700_bib6","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1080\/10428194.2017.1403018","article-title":"Clinical characteristics, therapy response, and outcome of 51 adult patients with hematological malignancy-associated hemophagocytic lymphohistiocytosis: a single institution experience","volume":"59","author":"Lorenz","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2025090911213696700_bib7","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3109\/10428194.2010.551153","article-title":"Malignancy-associated hemophagocytic lymphohistiocytosis in adults: a retrospective population-based analysis from a single center","volume":"52","author":"Machaczka","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"9927","key":"2025090911213696700_bib8","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(13)61048-X","article-title":"Adult haemophagocytic syndrome","volume":"383","author":"Ramos-Casals","year":"2014","journal-title":"Lancet"},{"issue":"8","key":"2025090911213696700_bib9","first-page":"997","article-title":"Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies","volume":"100","author":"Lehmberg","year":"2015","journal-title":"Haematologica"},{"issue":"5","key":"2025090911213696700_bib10","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s12185-019-02623-z","article-title":"Hemophagocytic lymphohistiocytosis as a harbinger of aggressive lymphoma: a case series","volume":"109","author":"Pasvolsky","year":"2019","journal-title":"Int J Hematol"},{"issue":"1","key":"2025090911213696700_bib11","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1182\/hematology.2023000509","article-title":"Inpatient recognition and management of HLH","volume":"2023","author":"Zoref-Lorenz","year":"2023","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"2","key":"2025090911213696700_bib12","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"2025090911213696700_bib13","doi-asserted-by":"crossref","first-page":"e27400","DOI":"10.1002\/pbc.27400","article-title":"Limitations of HLH-2004 criteria in distinguishing malignancy-associated hemophagocytic lymphohistiocytosis","volume":"65","author":"Gurunathan","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"18","key":"2025090911213696700_bib14","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1002\/cncr.30084","article-title":"Malignancy-associated hemophagocytic lymphohistiocytosis in adults: relation to hemophagocytosis, characteristics, and outcomes","volume":"122","author":"Tamamyan","year":"2016","journal-title":"Cancer"},{"issue":"7","key":"2025090911213696700_bib15","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1182\/blood.2021012764","article-title":"An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis","volume":"139","author":"Zoref-Lorenz","year":"2022","journal-title":"Blood"},{"issue":"14","key":"2025090911213696700_bib16","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","author":"International Non-Hodgkin's Lymphoma Prognostic Factors Project","year":"1993","journal-title":"N Engl J Med"},{"issue":"21","key":"2025090911213696700_bib17","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin's disease. International prognostic factors project on advanced Hodgkin's disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N Engl J Med"},{"issue":"5","key":"2025090911213696700_bib18","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma International Prognostic Index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"issue":"7","key":"2025090911213696700_bib19","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/cncr.30416","article-title":"A prospective cohort study of patients with peripheral T-cell lymphoma in the United States","volume":"123","author":"Carson","year":"2017","journal-title":"Cancer"},{"issue":"27","key":"2025090911213696700_bib20","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"2025090911213696700_bib21","unstructured":"National Center for Health Science\n          . Physicians\u2019 handbook on medical certification of death. Accessed 14 August 2023. https:\/\/www.cdc.gov\/nchs\/data\/misc\/hb_cod.pdf."},{"key":"2025090911213696700_bib22","unstructured":"National Center for Health Science\n          . Medical examiners\u2019 and coroners\u2019 handbook on death registration and fetal death reporting. Accessed 14 August 2023. https:\/\/www.cdc.gov\/nchs\/data\/misc\/hb_me.pdf."},{"issue":"1","key":"2025090911213696700_bib23","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.3324\/haematol.2019.220301","article-title":"Dose-adjusted EPOCH regimen as first-line treatment for non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis: a single-arm, open-label, phase II trial","volume":"105","author":"Liang","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"2025090911213696700_bib24","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1038\/s41467-023-38723-y","article-title":"Neutralizing IFN\u03b3 improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies","volume":"14","author":"Manni","year":"2023","journal-title":"Nat Commun"},{"issue":"7","key":"2025090911213696700_bib25","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1182\/bloodadvances.2020001497","article-title":"Efficacy of ruxolitinib in subcutaneous panniculitis-like T-cell lymphoma and hemophagocytic lymphohistiocytosis","volume":"4","author":"L\u00e9vy","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2025090911213696700_bib26","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/bjh.18817","article-title":"Efficacy of ruxolitinib for HAVCR2 mutation-associated hemophagocytic lymphohistiocytosis and panniculitis manifestations in children","volume":"202","author":"Zhang","year":"2023","journal-title":"Br J Haematol"},{"issue":"11","key":"2025090911213696700_bib27","doi-asserted-by":"crossref","first-page":"e28581","DOI":"10.1002\/pbc.28581","article-title":"The use of anakinra in the treatment of secondary hemophagocytic lymphohistiocytosis","volume":"67","author":"Bami","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"2025090911213696700_bib28","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1080\/10428194.2020.1849671","article-title":"The DEP regimen is superior to the HLH-1994 regimen as first-line therapy for lymphoma-associated haemophagocytic lymphohistiocytosis","volume":"62","author":"Meng","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2025090911213696700_bib29","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1007\/s00432-022-04157-0","article-title":"Modified DEP regimen as induction therapy for lymphoma-associated hemophagocytic lymphohistiocytosis: a prospective, multicenter study","volume":"149","author":"Pi","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"2025090911213696700_bib30","doi-asserted-by":"crossref","first-page":"e59456","DOI":"10.1371\/journal.pone.0059456","article-title":"Soluble and membrane-bound TGF-beta-mediated regulation of intratumoral T cell differentiation and function in B-cell non-Hodgkin lymphoma","volume":"8","author":"Yang","year":"2013","journal-title":"PLoS One"},{"issue":"12","key":"2025090911213696700_bib31","doi-asserted-by":"crossref","first-page":"E223","DOI":"10.1002\/ajh.23838","article-title":"Elevated soluble IL-2R\u03b1, IL-8, and MIP-1\u03b2 levels are associated with inferior outcome and are independent of MIPI score in patients with mantle cell lymphoma","volume":"89","author":"Sonbol","year":"2014","journal-title":"Am J Hematol"},{"issue":"10","key":"2025090911213696700_bib32","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1182\/blood-2011-03-340885","article-title":"Soluble IL-2R\u03b1 facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma","volume":"118","author":"Yang","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2025090911213696700_bib33","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/annonc\/mdv486","article-title":"Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2R\u03b1 as predictors of event-free survival in T-cell lymphoma","volume":"27","author":"Gupta","year":"2016","journal-title":"Ann Oncol"},{"issue":"20","key":"2025090911213696700_bib34","doi-asserted-by":"crossref","first-page":"5540","DOI":"10.1182\/blood-2011-04-351742","article-title":"Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity","volume":"118","author":"Elsawa","year":"2011","journal-title":"Blood"},{"key":"2025090911213696700_bib35","doi-asserted-by":"crossref","first-page":"823079","DOI":"10.3389\/fonc.2021.823079","article-title":"The addition of ferritin enhanced the prognostic value of International Prognostic Index in diffuse large B-cell lymphoma","volume":"11","author":"Shen","year":"2021","journal-title":"Front Oncol"},{"issue":"9","key":"2025090911213696700_bib36","doi-asserted-by":"crossref","first-page":"10660","DOI":"10.1002\/cam4.5820","article-title":"A novel prognostic model based on ferritin and nomogram-revised risk index could better stratify patients with extranodal natural killer\/T-cell lymphoma","volume":"12","author":"Liu","year":"2023","journal-title":"Cancer Med"},{"issue":"1","key":"2025090911213696700_bib37","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/ijlh.12592","article-title":"Serum ferritin level is a prognostic marker in patients with peripheral T-cell lymphoma","volume":"39","author":"Koyama","year":"2017","journal-title":"Int J Lab Hematol"},{"issue":"11","key":"2025090911213696700_bib38","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.3109\/10428194.2015.1038709","article-title":"Serum ferritin as prognostic marker in classical Hodgkin lymphoma treated with ABVD-based therapy","volume":"56","author":"Fernandez-Alvarez","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2025090911213696700_bib39","first-page":"474","article-title":"Serum soluble interleukin-2 receptor levels for screening for malignant lymphomas and differential diagnosis from other conditions","volume":"11","author":"Murakami","year":"2019","journal-title":"Mol Clin Oncol"},{"issue":"10","key":"2025090911213696700_bib40","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1007\/s00277-017-3072-0","article-title":"Elevated serum ferritin is not specific for hemophagocytic lymphohistiocytosis","volume":"96","author":"Otrock","year":"2017","journal-title":"Ann Hematol"},{"issue":"5","key":"2025090911213696700_bib41","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.4049\/jimmunol.135.5.3172","article-title":"Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro","volume":"135","author":"Rubin","year":"1985","journal-title":"J Immunol"},{"issue":"9","key":"2025090911213696700_bib42","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1182\/blood-2009-11-253815","article-title":"Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway","volume":"116","author":"Cohen","year":"2010","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/17\/4515\/2411303\/blooda_adv-2024-014005-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/17\/4515\/2411303\/blooda_adv-2024-014005-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T15:21:50Z","timestamp":1757431310000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/17\/4515\/536808\/The-OHI-index-predicts-early-mortality-from-organ"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":42,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2025,9,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014005","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9,9]]},"published":{"date-parts":[[2025,9,9]]}}}